---
layout: post
title: "Merck Sharp & Dohme Corp.; Withdrawal of Approval of New Drug Applications for VIOXX (Rofecoxib) Tablets and Suspension"
date: 2026-02-05 19:00:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-19740
original_published: 2022-09-13 00:00:00 +0000
significance: 8.00
---

# Merck Sharp & Dohme Corp.; Withdrawal of Approval of New Drug Applications for VIOXX (Rofecoxib) Tablets and Suspension

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 13, 2022 00:00 UTC
**Document Number:** 2022-19740

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug applications (NDAs) for VIOXX (rofecoxib) Tablets, 12.5 milligrams (mg), 25 mg, and 50 mg, and VIOXX (rofecoxib) Suspension, 12.5 mg/5 milliliter (mL) and 25 mg/5 mL, held by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., P.O. Box 100, 1 Merck Dr., Whitehouse Station, NJ 08889 (Merck). Merck has voluntarily requested that FDA withdraw approval of these applications and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/13/2022-19740/merck-sharp-and-dohme-corp-withdrawal-of-approval-of-new-drug-applications-for-vioxx-rofecoxib)
- API: https://www.federalregister.gov/api/v1/documents/2022-19740

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
